Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 146 articles: HTML format

Single Articles

May 2024
1. HO VKY, Deijen CL, Hemmes B, van Erning FN, et al
   Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021).
   Int J Cancer. 2024;154:1569-1578.
   PubMed     Abstract available
   
   
   April 2024
2. WEIJERS DD, Hirsch S, Bakhuizen JJ, van Engelen N, et al
   Molecular analysis of cancer genomes in children with Lynch syndrome: Exploring causal associations.
   Int J Cancer. 2024;154:1455-1463.
   PubMed     Abstract available
   
   
   
3. JIANG PC, Wang SW, Li C, Fan J, et al
   UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration.
   Int J Cancer. 2024;154:1484-1491.
   PubMed     Abstract available
   
   
   
4. FU X, Huang J, Zhu J, Fan X, et al
   Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model.
   Int J Cancer. 2024 Apr 9. doi: 10.1002/ijc.34946.
   PubMed     Abstract available
   
   
   
5. BOUVIER AM, Jooste V, Lillini R, Marcos-Gragera R, et al
   Differences in survival and recurrence of colorectal cancer by stage across population-based European registries.
   Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34944.
   PubMed     Abstract available
   
   
   
6. MOEN L, Liu B, Bukirwa P, Chingonzoh T, et al
   Trends in the incidence of colorectal cancer in sub-Saharan Africa: A population-based registry study.
   Int J Cancer. 2024 Apr 3. doi: 10.1002/ijc.34942.
   PubMed     Abstract available
   
   
   
7. BRENNER H, Weber L, Cardoso R, Heisser T, et al
   Indications of sustained delay of colorectal cancer diagnoses in Germany during the first 2 years of the COVID-19 pandemic.
   Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34943.
   PubMed    
   
   
   March 2024
8. LI YJ, Wang X, Wu YJ, Zhou XY, et al
   Access to colorectal cancer screening in populations in China, 2020: A coverage-focused synthesis analysis.
   Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34938.
   PubMed     Abstract available
   
   
   
9. TAN JY, Yeo YH, Ng WL, Fong ZV, et al
   How have US colorectal cancer mortality trends changed in the past 20 years?
   Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34926.
   PubMed     Abstract available
   
   
   
10. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed     Abstract available
    
    
    
11. ZNAOR A, Eser S, Bendahhou K, Shelpai W, et al
    Stage at diagnosis of colorectal cancer in the Middle East and Northern Africa: A population-based cancer registry study.
    Int J Cancer. 2024 Mar 8. doi: 10.1002/ijc.34895.
    PubMed     Abstract available
    
    
    
12. HORESH N, Emile SH, Garoufalia Z, Gefen R, et al
    Trends in management and outcomes of colon cancer in the United States over 15 years: Analysis of the National Cancer Database.
    Int J Cancer. 2024 Mar 7. doi: 10.1002/ijc.34910.
    PubMed     Abstract available
    
    
    
13. JEZIORSKI K
    Improving colon cancer screening in Poland. In search of the Holy Grail.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34909.
    PubMed    
    
    
    February 2024
14. MENG C, Sun L, Shi J, Li Y, et al
    Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis.
    Int J Cancer. 2024 Feb 22. doi: 10.1002/ijc.34891.
    PubMed     Abstract available
    
    
    
15. OYELERE AM, Kok DE, Bos D, Gunter MJ, et al
    Coffee consumption is associated with a reduced risk of colorectal cancer recurrence and all-cause mortality.
    Int J Cancer. 2024 Feb 12. doi: 10.1002/ijc.34879.
    PubMed     Abstract available
    
    
    
16. CHEN J, Terry MB, Dalerba P, Hur C, et al
    Environmental drivers of the rising incidence of early-onset colorectal cancer in the United States.
    Int J Cancer. 2024 Feb 10. doi: 10.1002/ijc.34887.
    PubMed     Abstract available
    
    
    
17. NORS J, Gotschalck KA, Erichsen R, Andersen CL, et al
    Incidence of late recurrence and second primary cancers 5-10 years after non-metastatic colorectal cancer.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34871.
    PubMed     Abstract available
    
    
    
18. NUMMELA P, Zafar S, Veikkolainen E, Ukkola I, et al
    GNAS mutation inhibits growth and induces phosphodiesterase 4D expression in colorectal cancer cell lines.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34865.
    PubMed     Abstract available
    
    
    
19. LEE V, Parkinson R, Zahurak M, Cope L, et al
    A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients.
    Int J Cancer. 2024 Feb 5. doi: 10.1002/ijc.34845.
    PubMed     Abstract available
    
    
    
20. HAMZA A, Masliah-Planchon J, Neuzillet C, Lefevre JH, et al
    Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection.
    Int J Cancer. 2024;154:504-515.
    PubMed     Abstract available
    
    
    
21. SAMUEL RJ, Gilbert DC
    Understanding the molecular biology of anal squamous cell carcinoma.
    Int J Cancer. 2024;154:410-411.
    PubMed    
    
    
    January 2024
22. STIER EA, Clarke MA, Deshmukh AA, Wentzensen N, et al
    International Anal Neoplasia Society's consensus guidelines for anal cancer screening.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34850.
    PubMed     Abstract available
    
    
    
23. PHAM TT, Nimptsch K, Aleksandrova K, Jenab M, et al
    Pre-diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study.
    Int J Cancer. 2024 Jan 10. doi: 10.1002/ijc.34830.
    PubMed     Abstract available
    
    
    
24. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    December 2023
25. BREEKVELDT ECH, Ykema BLM, Bisseling TM, Moons LMG, et al
    Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy.
    Int J Cancer. 2023 Dec 27. doi: 10.1002/ijc.34810.
    PubMed     Abstract available
    
    
    
26. PUIG-BLASCO L, Piotrowski KB, Michaelsen SR, Bager NS, et al
    Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors.
    Int J Cancer. 2023;153:2068-2081.
    PubMed     Abstract available
    
    
    
27. BARBER LE, Bertrand KA, Sheehy S, White LF, et al
    Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and occurrence of colorectal adenoma in Black American women.
    Int J Cancer. 2023;153:1978-1987.
    PubMed     Abstract available
    
    
    
28. ZHANG Q, Zhou Y, Song L, Fang W, et al
    China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.
    Int J Cancer. 2023;153:1885-1893.
    PubMed     Abstract available
    
    
    October 2023
29. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    PubMed     Abstract available
    
    
    
30. SROCZYNSKI G, Hallsson LR, Muhlberger N, Jahn B, et al
    Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk.
    Int J Cancer. 2023 Oct 5. doi: 10.1002/ijc.34747.
    PubMed     Abstract available
    
    
    September 2023
31. LIU Y, Bhardwaj S, Sigel K, Winters J, et al
    Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34734.
    PubMed     Abstract available
    
    
    
32. OSTERLUND E, Ristimaki A, Makinen MJ, Kytola S, et al
    Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
    Int J Cancer. 2023 Sep 19. doi: 10.1002/ijc.34733.
    PubMed     Abstract available
    
    
    
33. LINDMARK G, Olsson L, Sitohy B, Israelsson A, et al
    qRT-PCR analysis of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN in colon cancer lymph nodes-An improved method for assessment of tumor stage and prognosis.
    Int J Cancer. 2023 Sep 12. doi: 10.1002/ijc.34718.
    PubMed     Abstract available
    
    
    
34. GAO P, Mei Z, Liu Z, Zhu D, et al
    Association between serum urea concentrations and the risk of colorectal cancer, particularly in individuals with type 2 diabetes: A cohort study.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34719.
    PubMed     Abstract available
    
    
    August 2023
35. CONSTANTINESCU AE, Bull CJ, Jones N, Mitchell R, et al
    Circulating white blood cell traits and colorectal cancer risk: A Mendelian randomisation study.
    Int J Cancer. 2023 Aug 14. doi: 10.1002/ijc.34691.
    PubMed     Abstract available
    
    
    
36. 
    Correction to Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort study.
    Int J Cancer. 2023 Aug 10. doi: 10.1002/ijc.34654.
    PubMed    
    
    
    
37. PARK HA, Edelmann D, Canzian F, Seibold P, et al
    Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
    Int J Cancer. 2023 Aug 4. doi: 10.1002/ijc.34663.
    PubMed     Abstract available
    
    
    
38. YU L, Wang Z, Hu Y, Wang Y, et al
    Tumor-infiltrating gamma delta T-cells reveal exhausted subsets with remarkable heterogeneity in colorectal cancer.
    Int J Cancer. 2023 Aug 2. doi: 10.1002/ijc.34669.
    PubMed     Abstract available
    
    
    
39. DUGUE PA, Yu C, Hodge AM, Wong EM, et al
    Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer.
    Int J Cancer. 2023;153:489-498.
    PubMed     Abstract available
    
    
    July 2023
40. JIANG F, Boakye D, Sun J, Wang L, et al
    Association between antibiotic use during early life and early-onset colorectal cancer risk overall and according to polygenic risk and FUT2 genotypes.
    Int J Cancer. 2023 Jul 28. doi: 10.1002/ijc.34648.
    PubMed     Abstract available
    
    
    
41. D'ANGELO E, Pastrello C, Biccari A, Marangio A, et al
    An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.
    Int J Cancer. 2023;153:437-449.
    PubMed     Abstract available
    
    
    
42. CAO W, Hu H, Li J, Wu Q, et al
    China special issue on gastrointestinal tumor-radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trial.
    Int J Cancer. 2023 Jul 6. doi: 10.1002/ijc.34647.
    PubMed     Abstract available
    
    
    
43. MAROLLEAU P, Tougeron D, Allignet B, Cohen R, et al
    Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Int J Cancer. 2023 Jul 5. doi: 10.1002/ijc.34636.
    PubMed     Abstract available
    
    
    
44. DIAS GONCALVES LIMA F, Schim van der Loeff M
    Comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34641.
    PubMed    
    
    
    
45. NIKITINA E, Alikhanyan K, Nessling M, Richter K, et al
    Structural expression of bovine milk and meat factors in tissues of colorectal, lung and pancreatic cancer patients.
    Int J Cancer. 2023;153:173-182.
    PubMed     Abstract available
    
    
    
46. LIANG LA, Tseng YJ, Tanaka LF, Klug SJ, et al
    Second primary cancer among 217702 colorectal cancer survivors: An analysis of national German cancer registry data.
    Int J Cancer. 2023 Jul 1. doi: 10.1002/ijc.34638.
    PubMed     Abstract available
    
    
    June 2023
47. NAPOLITANO S, Ciardiello D, De Falco V, Martini G, et al
    Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
    Int J Cancer. 2023 Jun 30. doi: 10.1002/ijc.34632.
    PubMed     Abstract available
    
    
    
48. BEACH R, Hatano Y, Qiao Y, Grady J, et al
    Combination of naproxen and a chemically-stable eicosapentaenoic acid analog provide additive tumor protection in Pirc rats.
    Int J Cancer. 2023;152:2567-2579.
    PubMed     Abstract available
    
    
    
49. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Comments on "Epidemiology of overall and early-onset serrated polyps versus conventional adenomas in a colonoscopy screening cohort".
    Int J Cancer. 2023;152:2433-2435.
    PubMed    
    
    
    
50. KRONING H, Gohler T, Decker T, Grundeis M, et al
    Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34603.
    PubMed     Abstract available
    
    
    May 2023
51. KIM S, Cha Y, Lim Y, Roh H, et al
    Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.
    Int J Cancer. 2023 May 16. doi: 10.1002/ijc.34558.
    PubMed     Abstract available
    
    
    
52. AHADOVA A, Witt J, Haupt S, Gallon R, et al
    Is HLA type a possible cancer risk modifier in Lynch syndrome?
    Int J Cancer. 2023;152:2024-2031.
    PubMed     Abstract available
    
    
    
53. QUAN M, Chen J, Chen Z, Hai Y, et al
    Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study.
    Int J Cancer. 2023 May 10. doi: 10.1002/ijc.34531.
    PubMed     Abstract available
    
    
    
54. NYITRAY AG, Nitkowski J, McAuliffe TL, Brzezinski B, et al
    Home-based self-sampling vs clinician sampling for anal precancer screening: The Prevent Anal Cancer Self-Swab Study.
    Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34553.
    PubMed     Abstract available
    
    
    April 2023
55. FAN L, Cai Y, Wang H, Zhang H, et al
    Saturated fatty acid intake, genetic risk and colorectal cancer incidence: A large-scale prospective cohort study.
    Int J Cancer. 2023 Apr 23. doi: 10.1002/ijc.34544.
    PubMed     Abstract available
    
    
    
56. FANG L, Yao Y, Guan X, Liao Y, et al
    China special issue on gastrointestinal tumor: Regulatory-immunoscore-A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer.
    Int J Cancer. 2023 Apr 21. doi: 10.1002/ijc.34539.
    PubMed     Abstract available
    
    
    
57. GRINSHPUN A, Kustanovich A, Neiman D, Lehmann-Werman R, et al
    A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer.
    Int J Cancer. 2023;152:1444-1451.
    PubMed     Abstract available
    
    
    March 2023
58. DEBERIN J, Teles F, Martin LM, Lu J, et al
    Antibodies to Oral Pathobionts and Colon Cancer Risk in the CLUE I Cohort Study.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34527.
    PubMed     Abstract available
    
    
    
59. LI J, Qin S, Zhang S, Lu Y, et al
    Serum vitamin D concentration, vitamin D-related polymorphisms, and colorectal cancer risk.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34521.
    PubMed     Abstract available
    
    
    
60. VITHAYATHIL M, Smith S, Song M
    Epidemiology of overall and early-onset serrated polyps versus conventional adenomas in a colonoscopy screening cohort.
    Int J Cancer. 2023;152:1085-1094.
    PubMed     Abstract available
    
    
    
61. ALBUQUERQUE A
    Comments on "Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis": Prevention of anal squamous cell carcinoma in women: How to move forward: Prevention of anal squamous c
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34490.
    PubMed    
    
    
    
62. SIEVANEN T, Korhonen TM, Jokela T, Ahtiainen M, et al
    Systemic circulating microRNA landscape in Lynch syndrome.
    Int J Cancer. 2023;152:932-944.
    PubMed     Abstract available
    
    
    
63. HEISSER T, Cardoso R, Niedermaier T, Hoffmeister M, et al
    Making colonoscopy-based screening more efficient: A "gateopener" approach.
    Int J Cancer. 2023;152:952-961.
    PubMed     Abstract available
    
    
    February 2023
64. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    PubMed     Abstract available
    
    
    
65. YUAN S, Mason AM, Titova OE, Vithayathil M, et al
    Morning chronotype and digestive tract cancers: Mendelian randomization study.
    Int J Cancer. 2023;152:697-704.
    PubMed     Abstract available
    
    
    
66. YAO J, Chen Y, Lin Z
    Exosomes: Mediators in Microenvironment of Colorectal Cancer.
    Int J Cancer. 2023 Feb 9. doi: 10.1002/ijc.34471.
    PubMed     Abstract available
    
    
    
67. WANG K, Olen O, Emilsson L, Khalili H, et al
    Association of inflammatory bowel disease in first-degree relatives with risk of colorectal cancer: A nationwide case-control study in Sweden.
    Int J Cancer. 2023 Feb 9. doi: 10.1002/ijc.34470.
    PubMed     Abstract available
    
    
    
68. WANG Q, Shen X, Chen G, Du J, et al
    How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: from mechanisms to translation.
    Int J Cancer. 2023 Feb 8. doi: 10.1002/ijc.34464.
    PubMed     Abstract available
    
    
    
69. CHEN X, Heisser T, Cardoso R, Hoffmeister M, et al
    Overall and age-specific risk advancement periods of colorectal cancer for men versus women: implications for gender-sensitive screening offers?
    Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34455.
    PubMed     Abstract available
    
    
    
70. LV T, Shen L, Xu X, Yao Y, et al
    Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Int J Cancer. 2023;152:524-535.
    PubMed     Abstract available
    
    
    January 2023
71. MAO Z, Baker JR, Takeuchi M, Hyogo H, et al
    Pre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients.
    Int J Cancer. 2023 Jan 30. doi: 10.1002/ijc.34449.
    PubMed     Abstract available
    
    
    
72. BALTUSSEN JC, de Glas NA, Liefers GJ, Slingerland M, et al
    Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: a population-based study.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34422.
    PubMed     Abstract available
    
    
    
73. EEFSEN RL, Larsen JS, Klarskov LL, Altaf R, et al
    Therapy with pembrolizumab in treatment-naive patients with non-metastatic, mismatch repair deficient colorectal cancer.
    Int J Cancer. 2023 Jan 3. doi: 10.1002/ijc.34420.
    PubMed     Abstract available
    
    
    December 2022
74. REN J, Zhang P, Li Z, Zhang X, et al
    Association of screening status, polygenic risk score, and environmental risk factors with colorectal cancer incidence and mortality risks.
    Int J Cancer. 2022 Dec 20. doi: 10.1002/ijc.34407.
    PubMed     Abstract available
    
    
    
75. SHIMOMURA Y, Zha L, Komukai S, Narii N, et al
    Mediation effect of intestinal microbiota on the relationship between fiber intake and colorectal cancer.
    Int J Cancer. 2022 Dec 15. doi: 10.1002/ijc.34398.
    PubMed     Abstract available
    
    
    November 2022
76. BREEKVELDT ECH, Toes-Zoutendijk E, van de Schootbrugge-Vandermeer HJ, de Jonge L, et al
    Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34373.
    PubMed     Abstract available
    
    
    
77. SCHWARZ S, Hornschuch M, Pox C, Haug U, et al
    Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34375.
    PubMed     Abstract available
    
    
    
78. RIBE SG, Botteri E, Loberg M, Randel KR, et al
    Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34351.
    PubMed     Abstract available
    
    
    
79. VAN DER KRUIJSSEN DEW, van der Kuil AJS, Vink GR, Punt CJA, et al
    Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a population-based study and meta-analysis.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34347.
    PubMed     Abstract available
    
    
    October 2022
80. VAN DER MEER R, Bakkers C, van Erning FN, Simkens LHJ, et al
    A propensity score matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34325.
    PubMed     Abstract available
    
    
    
81. LI Z, Jia Y, Zhu H, Yuan H, et al
    Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
    Int J Cancer. 2022;151:1382-1393.
    PubMed     Abstract available
    
    
    September 2022
82. BETGE J, Jackstadt R
    From organoids to bedside: advances in modeling, decoding and targeting of colorectal cancer.
    Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34297.
    PubMed     Abstract available
    
    
    
83. GU Y, Duan B, Sha J, Zhang R, et al
    Serum IgG N-glycans Enable Early Detection and Early Relapse Prediction of Colorectal Cancer.
    Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34298.
    PubMed     Abstract available
    
    
    
84. WATTS K, Wills C, Madi A, Palles C, et al
    Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Int J Cancer. 2022;151:957-966.
    PubMed     Abstract available
    
    
    
85. SUN M, Bjorge T, Teleka S, Engeland A, et al
    Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study.
    Int J Cancer. 2022;151:859-868.
    PubMed     Abstract available
    
    
    
86. MARTIN-MORALES L, Manzano S, Rodrigo-Faus M, Vicente-Barrueco A, et al
    GERMLINE GAIN-OF-FUNCTION MMP11 VARIANT RESULTS IN AN AGGRESSIVE FORM OF COLORECTAL CANCER.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34289.
    PubMed     Abstract available
    
    
    
87. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available
    
    
    
88. BEGUM M, Lewison G, Wang X, Dunne PD, et al
    Global Colorectal Cancer Research, 2007-21: Outputs and Funding.
    Int J Cancer. 2022 Sep 8. doi: 10.1002/ijc.34279.
    PubMed     Abstract available
    
    
    August 2022
89. DESHMUKH AA, Damgacioglu H, Georges D, Sonawane K, et al
    Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis.
    Int J Cancer. 2022 Aug 28. doi: 10.1002/ijc.34269.
    PubMed     Abstract available
    
    
    
90. LJUNGGREN M, Weibull CE, Palmer G, Osterlund E, et al
    Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34255.
    PubMed     Abstract available
    
    
    
91. AKHOUNDOVA D, Hussung S, Sivakumar S, Topfer A, et al
    ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34257.
    PubMed     Abstract available
    
    
    
92. YIN L, Li H, Shi L, Chen K, et al
    Research Advances in Nanomedicine Applied to the Systemic Treatment of Colorectal Cancer.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34256.
    PubMed     Abstract available
    
    
    
93. VAN ROEKEL EH, Bours MJL, Breukink SO, Aquarius M, et al
    Longitudinal associations of plasma metabolites with persistent fatigue among colorectal cancer survivors up to 2 years after treatment.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34252.
    PubMed     Abstract available
    
    
    
94. LUKIC M, Licaj I, Laaksonen MA, Weiderpass E, et al
    The burden of colon cancer attributable to modifiable factors-The Norwegian Women and Cancer Study.
    Int J Cancer. 2022 Aug 10. doi: 10.1002/ijc.34237.
    PubMed     Abstract available
    
    
    
95. MARTINI G, Ciardiello D, Dallio M, Famiglietti V, et al
    Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Int J Cancer. 2022;151:473-480.
    PubMed     Abstract available
    
    
    
96. HARLID S, Van Guelpen B, Qu C, Gylling B, et al
    Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.
    Int J Cancer. 2022;151:348-360.
    PubMed     Abstract available
    
    
    July 2022
97. VAN BLARIGAN EL, Ma C, Ou FS, Bainter TM, et al
    Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34230.
    PubMed     Abstract available
    
    
    
98. XU X, Duan X, Wang S, Zhang Y, et al
    Special issue "The advance of solid tumor research in China": Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signaling.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34227.
    PubMed     Abstract available
    
    
    
99. DIAS CARVALHO P, Martins F, Mendonca S, Ribeiro A, et al
    Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis.
    Int J Cancer. 2022 Jul 23. doi: 10.1002/ijc.34225.
    PubMed     Abstract available
    
    
    
100. LIU T, Zhang Q, Song C, Siyin ST, et al
     C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study.
     Int J Cancer. 2022;151:297-307.
     PubMed     Abstract available
     
     
     
101. CLARKE MA, Deshmukh AA, Suk R, Roberts J, et al
     A Systematic Review and Meta-Analysis of Cytology and HPV-related Biomarkers for Anal Cancer Screening Among Different Risk Groups.
     Int J Cancer. 2022 Jul 6. doi: 10.1002/ijc.34199.
     PubMed     Abstract available
     
     
     
102. ROELANDT P, Droogne W, Voros G, Van Aelst L, et al
     Are heart transplant recipients more at risk for anal squamous carcinoma than other solid organ transplant recipients?
     Int J Cancer. 2022;151:156-157.
     PubMed    
     
     
     
103. ACHILLI P, Magistro C, Abd El Aziz MA, Calini G, et al
     Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world.
     Int J Cancer. 2022;151:120-127.
     PubMed     Abstract available
     
     
     
104. LI J, You L, Xu Z, Bai H, et al
     Healthy lifestyle and the risk of conventional adenomas and serrated polyps: Findings from a large colonoscopy screening population.
     Int J Cancer. 2022;151:67-76.
     PubMed     Abstract available
     
     
     
105. SOLOMON A, Alteber Z, Bassan D, Sharbi-Yunger A, et al
     On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
     Int J Cancer. 2022;151:107-119.
     PubMed     Abstract available
     
     
     June 2022
106. PING J, Yang Y, Wen W, Kweon SS, et al
     Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians.
     Int J Cancer. 2022 Jun 29. doi: 10.1002/ijc.34194.
     PubMed     Abstract available
     
     
     
107. FATEMI N, Tierling S, Es HA, Varkiani M, et al
     DNA Methylation Biomarkers in Colorectal Cancer: Clinical Applications for Precision Medicine.
     Int J Cancer. 2022 Jun 22. doi: 10.1002/ijc.34186.
     PubMed     Abstract available
     
     
     
108. WATANABE J, Maeda H, Nagasaka T, Yokota M, et al
     Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer - Exploratory sequential examination of acquired mutations in circulating cell-free DN
     Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34184.
     PubMed     Abstract available
     
     
     
109. JIANG Z, Yang Z
     Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage.
     Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34175.
     PubMed    
     
     
     
110. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
     Reply to "Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage".
     Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34177.
     PubMed    
     
     
     
111. WANG L, Knudsen MD, Lo CH, Wang K, et al
     Adherence to a healthy lifestyle in relation to colorectal cancer incidence and all-cause mortality after endoscopic polypectomy: a prospective study in three U.S. cohorts.
     Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34176.
     PubMed     Abstract available
     
     
     
112. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
     Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
     Int J Cancer. 2022;150:1978-1986.
     PubMed     Abstract available
     
     
     
113. TORREGROSA C, Pernot S, Vaflard P, Perret A, et al
     FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
     Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34166.
     PubMed     Abstract available
     
     
     
114. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
     The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
     Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
     PubMed     Abstract available
     
     
     
115. RAIMONDI A, Randon G, Prisciandaro M, Pagani F, et al
     Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial.
     Int J Cancer. 2022 Jun 9. doi: 10.1002/ijc.34156.
     PubMed     Abstract available
     
     
     
116. BAMBERG LV, Heigwer F, Wandmacher AM, Singh A, et al
     Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
     Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34155.
     PubMed     Abstract available
     
     
     
117. VAN ROOIJEN KL, Derksen JWG, Verkooijen HM, Vink GR, et al
     Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34149.
     PubMed     Abstract available
     
     
     
118. ELMAHDI R, Wennerstrom ECM, Andersson M, Wohlfahrt J, et al
     Shared Environment and Colorectal Cancer: A Nordic Pedigree Registry-based Cohort Study.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34148.
     PubMed     Abstract available
     
     
     
119. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
     Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
     PubMed     Abstract available
     
     
     
120. FABER MT, Frederiksen K, Palefsky JM, Kjaer SK, et al
     A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34143.
     PubMed     Abstract available
     
     
     May 2022
121. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
     Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
     Int J Cancer. 2022;150:1537-1548.
     PubMed     Abstract available
     
     
     April 2022
122. VAN DIJK E, van Werkhoven E, Asher R, Mooi JK, et al
     Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer; a post-hoc analysis of the randomized phase III-trial AGITG-MAX.
     Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34061.
     PubMed     Abstract available
     
     
     
123. LI M, Gong J, Bao Y, Huang D, et al
     Special issue "The advance of solid tumor research in China": Prognosis prediction for stage II colorectal cancer by fusing CT radiomics and deep-learning features of primary lesions and peripheral lymph nodes.
     Int J Cancer. 2022 Apr 29. doi: 10.1002/ijc.34053.
     PubMed     Abstract available
     
     
     
124. CHEN LJ, Nguyen TNM, Chang-Claude J, Hoffmeister M, et al
     Incorporation of functional status, frailty, comorbidities, and co-medication in prediction models for colorectal cancer survival.
     Int J Cancer. 2022 Apr 18. doi: 10.1002/ijc.34036.
     PubMed     Abstract available
     
     
     
125. BOTTERI E, Hoff G, Randel KR, Holme O, et al
     Characteristics of non-participants in a randomized colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing.
     Int J Cancer. 2022 Apr 12. doi: 10.1002/ijc.34025.
     PubMed     Abstract available
     
     
     February 2022
126. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
     Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation through IL-6-induced regulation of DNA damage in vitro.
     Int J Cancer. 2022 Feb 25. doi: 10.1002/ijc.33982.
     PubMed     Abstract available
     
     
     
127. OH CR, Kim JE, Hong YS, Kim SY, et al
     Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
     Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33966.
     PubMed     Abstract available
     
     
     
128. IERACI L, Eberg M, Forster K, Murray PM, et al
     Development of population-level colon cancer pathway concordance measures and association with survival.
     Int J Cancer. 2022 Feb 16. doi: 10.1002/ijc.33964.
     PubMed     Abstract available
     
     
     
129. GEBHARD C, Mulet-Lazaro R, Glatz D, Schwarzfischer-Pfeilschifter L, et al
     Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype.
     Int J Cancer. 2022;150:617-625.
     PubMed     Abstract available
     
     
     
130. MIAO Y, Xu Z, Feng W, Zheng M, et al
     Platelet infiltration predicts survival in postsurgical colorectal cancer patients.
     Int J Cancer. 2022;150:509-520.
     PubMed     Abstract available
     
     
     January 2022
131. LUU XQ, Lee K, Jun JK, Suh M, et al
     Effect of colorectal cancer screening on long-term survival of colorectal cancer patients: Results of the Korea National Cancer Screening Program.
     Int J Cancer. 2022 Jan 31. doi: 10.1002/ijc.33953.
     PubMed     Abstract available
     
     
     
132. AO T, Mochizuki S, Kajiwara Y, Yonemura K, et al
     Cancer-associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: potential role of ADAM9.
     Int J Cancer. 2022 Jan 26. doi: 10.1002/ijc.33947.
     PubMed     Abstract available
     
     
     
133. ZHOU X, Wang L, Xiao J, Sun J, et al
     Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis.
     Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33945.
     PubMed     Abstract available
     
     
     
134. JENNISKENS JCA, Offermans K, Simons CCJM, Samarska I, et al
     Energy balance-related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg-effect.
     Int J Cancer. 2022 Jan 22. doi: 10.1002/ijc.33941.
     PubMed     Abstract available
     
     
     
135. TORTORA K, Margheri F, Luceri C, Mocali A, et al
     Colon fibroblasts from Pirc rats (F344/NTac-Apc(am1137) ) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis.
     Int J Cancer. 2022;150:362-373.
     PubMed     Abstract available
     
     
     
136. KEMPF E, Priou S, Lame G, Daniel C, et al
     Impact of two waves of Sars-Cov2 outbreak on the number, clinical presentation, care trajectories and survival of patients newly referred for a colorectal cancer: A French multicentric cohort study from a large group of University hospitals.
     Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33928.
     PubMed     Abstract available
     
     
     
137. YU YC, Paragomi P, Wang R, Jin A, et al
     Composite Dietary Antioxidant Index and the Risk of Colorectal Cancer: Findings from the Singapore Chinese Health Study.
     Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33925.
     PubMed     Abstract available
     
     
     December 2021
138. VANGALA DB, Ladigan-Badura S, Engel C, Huneburg R, et al
     Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome.
     Int J Cancer. 2021;149:2052-2062.
     PubMed     Abstract available
     
     
     
139. HUANG Y, Hua X, Labadie JD, Harrison TA, et al
     Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex- and lifestyle factors- specific associations.
     Int J Cancer. 2021 Dec 9. doi: 10.1002/ijc.33897.
     PubMed     Abstract available
     
     
     
140. HEISSER T, Hoffmeister M, Brenner H
     Model based evaluation of long-term efficacy of existing and alternative colorectal cancer screening offers: A case study for Germany.
     Int J Cancer. 2021 Dec 8. doi: 10.1002/ijc.33894.
     PubMed     Abstract available
     
     
     
141. LUU HN, Tran MT, Nguyen MV, Tuong TT, et al
     Association between body mass index and colorectal adenomas: Findings from a case-control study in Vietnam.
     Int J Cancer. 2021;149:1898-1909.
     PubMed     Abstract available
     
     
     
142. NIEDERMAIER T, Heisser T, Gies A, Guo F, et al
     To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population.
     Int J Cancer. 2021;149:1877-1886.
     PubMed     Abstract available
     
     
     November 2021
143. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
     Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
     Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
     PubMed     Abstract available
     
     
     October 2021
144. ZHU Y, Huang Y, Hu Y, Fang Y, et al
     Long-term Risk of Colorectal Cancer after Removal of Adenomas during Screening Colonoscopies in a Large Community-based Population in China.
     Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33835.
     PubMed     Abstract available
     
     
     August 2021
145. ZHAO S, Chen L, Zang Y, Liu W, et al
     Endometrial cancer in lynch syndrome.
     Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33763.
     PubMed     Abstract available
     
     
     July 2021
146. VAN DER ZEE RP, Meijer CJLM, Cuming T, Kreuter A, et al
     Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki-67, HPV-E4, and DNA methylation markers.
     Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33748.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.